193 related articles for article (PubMed ID: 35838362)
1. Update in approaches to pulmonary hypertension because of left heart disease.
Kennedy JLW; Mihalek AD
Curr Opin Pulm Med; 2022 Sep; 28(5):337-342. PubMed ID: 35838362
[TBL] [Abstract][Full Text] [Related]
2. [Pulmonary hypertension associated with left heart disease (group 2)].
Schmidt KH; Bikou O; Blindt R; Bruch L; Felgendreher R; Hohenforst-Schmidt W; Holt S; Ladage D; Pfeuffer-Jovic E; Rieth A; Schmeisser A; Schnitzler K; Stadler S; Steringer-Mascherbauer R; Yogeswaran A; Kuebler WM
Pneumologie; 2023 Nov; 77(11):926-936. PubMed ID: 37963482
[TBL] [Abstract][Full Text] [Related]
3. Pulmonary Hypertension in Heart Failure.
Jang AY; Park SJ; Chung WJ
Int J Heart Fail; 2021 Jul; 3(3):147-159. PubMed ID: 36262642
[TBL] [Abstract][Full Text] [Related]
4. Pulmonary Hypertension Due to Left Heart Disease-A Practical Approach to Diagnosis and Management.
Lee F; Mielniczuk LM
Can J Cardiol; 2021 Apr; 37(4):572-584. PubMed ID: 33217522
[TBL] [Abstract][Full Text] [Related]
5. Corrected MRI Pulmonary Transit Time for Identification of Combined Precapillary and Postcapillary Pulmonary Hypertension in Patients With Left Heart Disease.
Gong C; Guo X; Wan K; Chen C; Chen X; Guo J; He J; Yin L; Wen B; Pu S; Chen Y
J Magn Reson Imaging; 2023 May; 57(5):1518-1528. PubMed ID: 37021578
[TBL] [Abstract][Full Text] [Related]
6. Combined post- and pre-capillary pulmonary hypertension in heart failure with preserved ejection fraction.
Dixon DD; Trivedi A; Shah SJ
Heart Fail Rev; 2016 May; 21(3):285-97. PubMed ID: 26714826
[TBL] [Abstract][Full Text] [Related]
7. Updates in the Pharmacotherapy of Pulmonary Hypertension in Patients with Heart Failure with Preserved Ejection Fraction.
Segovia F; Garcia H; Alkhateeb H; Mukherjee D; Nickel N
Cardiovasc Hematol Disord Drug Targets; 2023; 23(4):215-225. PubMed ID: 37921162
[TBL] [Abstract][Full Text] [Related]
8. Pulmonary Hypertension in the Context of Heart Failure With Preserved Ejection Fraction.
Inampudi C; Silverman D; Simon MA; Leary PJ; Sharma K; Houston BA; Vachiéry JL; Haddad F; Tedford RJ
Chest; 2021 Dec; 160(6):2232-2246. PubMed ID: 34391755
[TBL] [Abstract][Full Text] [Related]
9. [Pulmonary hypertension associated with left heart disease (group 2)].
Wissmüller M; Tichelbäcker T; Finke K; Dohr J; Adler J; Ochs L; Hohmann C; Baldus S; Rosenkranz S
Dtsch Med Wochenschr; 2023 Nov; 148(23):1498-1506. PubMed ID: 37949078
[TBL] [Abstract][Full Text] [Related]
10. Management of Pulmonary Hypertension in Left Heart Disease.
Macera F; Vachiéry JL
Methodist Debakey Cardiovasc J; 2021; 17(2):115-123. PubMed ID: 34326931
[TBL] [Abstract][Full Text] [Related]
11. Pulmonary hypertension associated with left heart disease.
Wissmüller M; Dohr J; Adler J; Ochs L; Tichelbäcker T; Hohmann C; Baldus S; Rosenkranz S
Herz; 2023 Aug; 48(4):266-273. PubMed ID: 37289211
[TBL] [Abstract][Full Text] [Related]
12. Pulmonary hypertension associated with left-sided heart failure.
Adler J; Gerhardt F; Wissmüller M; Adler C; Baldus S; Rosenkranz S
Curr Opin Cardiol; 2020 Nov; 35(6):610-619. PubMed ID: 32969856
[TBL] [Abstract][Full Text] [Related]
13. Pulmonary vascular disease in pulmonary hypertension due to left heart disease: pathophysiologic implications.
Omote K; Sorimachi H; Obokata M; Reddy YNV; Verbrugge FH; Omar M; DuBrock HM; Redfield MM; Borlaug BA
Eur Heart J; 2022 Sep; 43(36):3417-3431. PubMed ID: 35796488
[TBL] [Abstract][Full Text] [Related]
14. Pulmonary Hypertension Due to Left Heart Disease: Diagnosis, Pathophysiology, and Therapy.
Al-Omary MS; Sugito S; Boyle AJ; Sverdlov AL; Collins NJ
Hypertension; 2020 Jun; 75(6):1397-1408. PubMed ID: 32336230
[TBL] [Abstract][Full Text] [Related]
15. Clinical phenotypes and outcomes of pulmonary hypertension due to left heart disease: Role of the pre-capillary component.
Caravita S; Faini A; Carolino D'Araujo S; Dewachter C; Chomette L; Bondue A; Naeije R; Parati G; Vachiéry JL
PLoS One; 2018; 13(6):e0199164. PubMed ID: 29920539
[TBL] [Abstract][Full Text] [Related]
16. Left ventricular heart failure and pulmonary hypertension.
Rosenkranz S; Gibbs JS; Wachter R; De Marco T; Vonk-Noordegraaf A; Vachiéry JL
Eur Heart J; 2016 Mar; 37(12):942-54. PubMed ID: 26508169
[TBL] [Abstract][Full Text] [Related]
17. The future of group 2 pulmonary hypertension: Exploring clinical trials and therapeutic targets.
Awada C; Boucherat O; Provencher S; Bonnet S; Potus F
Vascul Pharmacol; 2023 Aug; 151():107180. PubMed ID: 37178949
[TBL] [Abstract][Full Text] [Related]
18. Treatment of advanced group 2 PH.
Barnett CF; De Marco T
Prog Cardiovasc Dis; 2016; 59(1):78-86. PubMed ID: 27417251
[TBL] [Abstract][Full Text] [Related]
19. Omics and Extreme Phenotyping Reveal Longitudinal Association Between Left Atrial Size and Pulmonary Vascular Resistance in Group 2 Pulmonary Hypertension.
Kelly NJ; Newhouse D; Chapagain H; Patel A; Tang Y; Howard A; Kirillova A; Kim HJ; Rahman H; El Khoury W; Nouraie SM; Hickey G; Sade LE; Jain S; Chan SY
J Am Heart Assoc; 2023 Dec; 12(23):e031746. PubMed ID: 38014658
[TBL] [Abstract][Full Text] [Related]
20. Pulmonary hypertension with a precapillary component in heart failure with preserved ejection fraction.
Sera F; Ohtani T; Tamaki S; Yano M; Hayashi T; Nakagawa A; Nakagawa Y; Nakatani D; Yamada T; Yasumura Y; Hikoso S; Yamauchi-Takihara K; Sakata Y;
Heart; 2023 Mar; 109(8):626-633. PubMed ID: 36543519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
